加载中
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
前收盘价
US$17.98
+US$0.10 · +0.56%
盘前
US$17.22
−US$0.76 · -4.23%
10月13日 8:24 ET
盘中时间采用ET。市场数据可能有所延迟。
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
日内区间
当前US$17.98
52周区间
当前US$17.98
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
39
偏贵
情绪
58
多空交织
风险
46
风险偏高
动量
71
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
日内区间
当前US$17.98
52周区间
当前US$17.98
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1535.5万 USD | 1000.7万 USD | 2554.6万 USD | 138.1万 USD | 302.9万 USD |
| 销货成本 | 355.7万 USD | 3.15亿 USD | 3.26亿 USD | 2.43亿 USD | 1.69亿 USD |
| 毛利 | 1179.8万 USD | −3.05亿 USD | −3.01亿 USD | −2.42亿 USD | −1.66亿 USD |
| 研究与开发 | 2.61亿 USD | 3.19亿 USD | 3.3亿 USD | 2.46亿 USD | 2.96亿 USD |
| 销售、一般及管理费用 | 5671万 USD | 8024万 USD | 7858.1万 USD | 6932.8万 USD | 5974.8万 USD |
| 营业费用 | 3.15亿 USD | 6703.4万 USD | 7215.9万 USD | 5765.1万 USD | 1.98亿 USD |
| 利息收入 | 2703.5万 USD | 3474.6万 USD | 3104.5万 USD | 878.6万 USD | 83万 USD |
| 折旧和摊销 | 355.7万 USD | 546.4万 USD | 526.9万 USD | 413万 USD | 392.5万 USD |
| 营业利润 | −3.03亿 USD | −3.72亿 USD | −3.73亿 USD | −2.99亿 USD | −3.65亿 USD |
| 净利润 | −2.76亿 USD | −3.38亿 USD | −3.42亿 USD | −2.91亿 USD | −3.64亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$26.25
上涨空间 46.00%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.25亿0.01%2.3万亿 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI8559.74万0.87%103.03亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM8510.65万0.11%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF3620.53万0.04%954亿 USD0.05%US$233.52-0.63%
iShares Biotechnology ETFIBB2378.06万0.22%108.2亿 USD0.44%US$204.26-1.08%
iShares Russell 2000 Growth ETFIWO2367.04万0.17%139.17亿 USD0.24%US$353.71-0.86%
Dimensional - US Small Cap ETFDFAS2252.96万0.07%338.04亿 USD0.31%US$78.17-0.23%
T. Rowe Capital Appreciation Equity ETFTCAF1806.14万0.20%91.19亿 USD0.31%US$43.56-0.07%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFAST. Rowe Capital Appreciation Equity ETFTCAFAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
